TP53 and ovarian cancer: Furthermore, ovarian cancer cells perhaps “strategically” keep the tumor suppressor miR-23b at lower expression to maintain proliferative status by increasing the expression of its oncogenic target CCNG1 (cyclin G1) to sufficient levels to activate Mdm2 and ultimately override inhibitory effects of the wild-type p53 (73, 74).